Peripartum cardiomyopathy

Evidence-Based Cardiology Consult

Volumn , Issue , 2013, Pages 471-480

  Kfoury, Abdallah Georges ^a   Rasmusson, Kismet D ^b   Brunisholz, Kimberly D ^a   Porter, T Flint ^c   Horne, Benjamin D ^c  

^a INTERMOUNTAIN MEDICAL CENTER   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Heart failure; Peripartum cardiomyopathy; Pregnancy

Indexed keywords

EID: 84928923555     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4471-4441-0_33     Document Type: Chapter

References (70)

1. Richie C. Clinical contributions to the pathology, diagnosis, and treatment of certain chronic disease of the heart. Edinb Med Surg J. 1849;2(333).
2. Hull E, Hafkesbring E. ?Toxic? postpartal heart disease. New Orleans Med Surg J. 1937;89:550.
3. Demakis JG, Rahimtoola SH. Peripartum cardiomyopathy. Circulation. 1971;44(5):964-8.
4. Pearson GD, et al. Peripartum cardiomyopathy: national heart, lung, and blood institute and office of rare diseases (National Institutes of Health) workshop recommendations and review. JAMA. 2000;283(9):1183-8.
5. Sliwa K, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010;12(8):767-78.
6. Mielniczuk LM, et al. Frequency of peripartum cardiomyopathy. Am J Cardiol. 2006;97(12):1765-8.
7. Pyatt JR, Dubey G. Peripartum cardiomyopathy: current understanding, comprehensive management review and new developments. Postgrad Med J. 2011;87(1023):34-9.
8. Goland S, et al. Clinical profi le and predictors of complications in peripartum cardiomyopathy. J Card Fail. 2009;15(8):645-50.
9. Elkayam U, et al. Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Circulation. 2005;111(16):2050-5.
10. Sliwa K, et al. Outcome of subsequent pregnancy in patients with documented peripartum cardiomyopathy. Am J Cardiol. 2004; 93(11):1441-3, A10.
11. Sliwa K, Tibazarwa K, Hilfi ker-Kleiner D. Management of peripartum cardiomyopathy. Curr Heart Fail Rep. 2008;5(4):238-44.
12. Gunderson EP, et al. Epidemiology of peripartum cardiomyopathy: incidence, predictors, and outcomes. Obstet Gynecol. 2011;118(3): 583-91.
13. Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. Lancet. 2006;368(9536):687-93.
14. Corbacho AM, Martinez De La Escalera G, Clapp C. Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. J Endocrinol. 2002;173(2): 219-38.
15. Hilfi ker-Kleiner D, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2007;128(3): 589-600.
16. Hilfi ker-Kleiner D, Sliwa K, Drexler H. Peripartum cardiomyopathy: recent insights in its pathophysiology. Trends Cardiovasc Med. 2008;18(5):173-9.
17. Hilfi ker-Kleiner D, et al. Recovery from postpartum cardiomyopathy in 2 patients by blocking prolactin release with bromocriptine. J Am Coll Cardiol. 2007;50(24):2354-5.
18. Sliwa K, et al. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J. 2006;27(4):441-6.
19. Forster O, et al. Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. Eur J Heart Fail. 2008;10(9):861-8.
20. Sliwa K, et al. The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. Eur J Heart Fail. 2002;4(3):305-9.
21. Fett JD. Viral infection as a possible trigger for the development of peripartum cardiomyopathy. Int J Gynaecol Obstet. 2007;97(2): 149-50.
22. Sanderson JE, Olsen EG, Gatei D. Peripartum heart disease: an endomyocardial biopsy study. Br Heart J. 1986;56(3):285-91.
23. Midei MG, et al. Peripartum myocarditis and cardiomyopathy. Circulation. 1990;81(3):922-8.
24. Felker GM, et al. Myocarditis and long-term survival in peripartum cardiomyopathy. Am Heart J. 2000;140(5):785-91.
25. Bultmann BD, et al. High prevalence of viral genomes and inflammation in peripartum cardiomyopathy. Am J Obstet Gynecol. 2005; 193(2):363-5.
26. Ansari AA, et al. Autoimmune mechanisms as the basis for human peripartum cardiomyopathy. Clin Rev Allergy Immunol. 2002; 23(3):301-24.
27. Lamparter S, Pankuweit S, Maisch B. Clinical and immunologic characteristics in peripartum cardiomyopathy. Int J Cardiol. 2007; 118(1):14-20.
28. Warraich RS, et al. Impact of pregnancy-related heart failure on humoral immunity: clinical relevance of G3-subclass immunoglobulins in peripartum cardiomyopathy. Am Heart J. 2005;150(2): 263-9.
29. Maron BJ, et al. Contemporary defi nitions and classifi cation of the cardiomyopathies: an American Heart Association Scientifi c Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113(14):1807-16.
30. Elliott P, et al. Classifi cation of the cardiomyopathies. Kardiol Pol. 2008;66(5):533-40; discussion 541-2.
31. Massad LS, et al. Familial peripartum cardiomyopathy after molar pregnancy. Obstet Gynecol. 1993;81(5 (Pt 2)):886-8.
32. Pierce JA, Price BO, Joyce JW. Familial occurrence of postpartal heart failure. Arch Intern Med. 1963;111:651-5.
33. Pearl W. Familial occurrence of peripartum cardiomyopathy. Am Heart J. 1995;129(2):421-2.
34. Fett JD, et al. Mother-daughter peripartum cardiomyopathy. Int J Cardiol. 2002;86(2-3):331-2.
35. Cowan J, et al. Genetic testing and genetic counseling in cardiovascular genetic medicine: overview and preliminary recommendations. Congest Heart Fail. 2008;14(2):97-105.
36. van Spaendonck-Zwarts KY, et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation. 2010;121(20): 2169-75.
37. Morales A, et al. Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy. Circulation. 2010;121(20):2176-82.
38. Horne BD, et al. Genome-wide signifi cance and replication of the chromosome 12p11.22 locus near the PTHLH gene for peripartum cardiomyopathy. Circ Cardiovasc Genet. 2011;4(4):359-66.
39. Fett JD. Validation of a self-test for early diagnosis of heart failure in peripartum cardiomyopathy. Crit Pathw Cardiol. 2011;10(1): 44-5.
40. Ray P, Murphy GJ, Shutt LE. Recognition and management of maternal cardiac disease in pregnancy. Br J Anaesth. 2004;93(3): 428-39.
41. Abboud J, et al. Peripartum cardiomyopathy: a comprehensive review. Int J Cardiol. 2007;118(3):295-303.
42. Renz DM, et al. New insights into peripartum cardiomyopathy using cardiac magnetic resonance imaging. Rofo. 2011;183(9):834-41.
43. Mouquet F, et al. Characterisation of peripartum cardiomyopathy by cardiac magnetic resonance imaging. Eur Radiol. 2008;18(12): 2765-9.
44. Hunt SA, et al. 2009 focused update incorporated into the ACC/ AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009; 119(14):e391-479.
45. Cooper LT, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientifi c statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation. 2007;116(19): 2216-33.
46. Hu CL, et al. Troponin T measurement can predict persistent left ventricular dysfunction in peripartum cardiomyopathy. Heart. 2007;93(4):488-90.
47. Velickovic IA, Leicht CH. Peripartum cardiomyopathy and cesarean section: report of two cases and literature review. Arch Gynecol Obstet. 2004;270(4):307-10.
48. Elkayam U. Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management. J Am Coll Cardiol. 2011;58(7):659-70.
49. Goland S, et al. Evaluation of the clinical relevance of baseline left ventricular ejection fraction as a predictor of recovery or persistence of severe dysfunction in women in the United States with peripartum cardiomyopathy. J Card Fail. 2011;17(5):426-30.
50. Safi rstein JG, et al. Predictors of left ventricular recovery in a cohort of peripartum cardiomyopathy patients recruited via the internet. Int J Cardiol. 2012;154(1):27-31.
51. Amos AM, Jaber WA, Russell SD. Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J. 2006;152(3): 509-13.
52. Francis GS, et al. ACCF/AHA/ACP/HFSA/ISHLT 2010 clinical competence statement on management of patients with advanced heart failure and cardiac transplant: a report of the ACCF/AHA/ ACP Task Force on Clinical Competence and Training. J Am Coll Cardiol. 2010;56(5):424-53.
53. Gynaecologists R.C.o.O.a. Reducing the risk of thromboembolism during pregnancy, birth, and the puerperium. Guideline no. 37. 2009;London: RCOG.
54. James AH, et al. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol. 2006;194(5):1311-5.
55. Holzgreve W, Carey JC, Hall BD. Warfarin-induced fetal abnormalities. Lancet. 1976;2(7991):914-5.
56. Bozkurt B, et al. Intravenous immune globulin in the therapy of peripartum cardiomyopathy. J Am Coll Cardiol. 1999;34(1):177-80.
57. Fett JD. Personal commentary: monitoring subsequent pregnancy in recovered peripartum cardiomyopathy mothers. Crit Pathw Cardiol. 2009;8(4):172-4.
58. Elkayam U, et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N Engl J Med. 2001;344(21):1567-71.
59. Karaye KM, Henein MY. Peripartum cardiomyopathy: a review article. Int J Cardiol. 2013;164(1):33-8.
60. Fett JD, Christie LG, Murphy JG. Brief communication: outcomes of subsequent pregnancy after peripartum cardiomyopathy: a case series from Haiti. Ann Intern Med. 2006;145(1):30-4.
61. Reimold SC, Rutherford JD. Peripartum cardiomyopathy. N Engl J Med. 2001;344(21):1629-30.
62. Elkayam U, Goland S. Bromocriptine for the treatment of peripartum cardiomyopathy. Circulation. 2010;121(13):1463-4.
63. Ecker JL, Frigoletto Jr FD. Cesarean delivery and the risk-benefi t calculus. N Engl J Med. 2007;356(9):885-8.
64. Cooper LT, et al. Myocardial recovery in peripartum cardiomyopathy: prospective comparison with recent onset cardiomyopathy in men and nonperipartum women. J Card Fail. 2012;18(1):28-33.
65. Rasmusson K, et al. Long term outcomes in patients with peripartum cardiomyopathy and no recovery of left ventricular function. J Card Fail. 2010;16:S97.
66. Witlin AG, Mabie WC, Sibai BM. Peripartum cardiomyopathy: an ominous diagnosis. Am J Obstet Gynecol. 1997;176(1 Pt 1): 182-8.
67. Rasmusson K, et al. Peripartum cardiomyopathy: post-transplant outcomes from the united network for organ sharing database. J Heart Lung Transplant. 2012;31(2):180-6.
68. Rasmusson K, et al. Predictors of graft survival in heart transplant recipients with peripartum cardiomyopathy: insights from the United Network for Organ Sharing (UNOS) database. J Heart Lung Transplant. 2012;31(4S):S137.
69. Fett JD, et al. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin Proc. 2005;80(12):1602-6.
70. Brar SS, et al. Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am J Cardiol. 2007;100(2):302-4.